Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sean Maduck Sells 18,303 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 18,303 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $60.69, for a total value of $1,110,809.07. Following the completion of the transaction, the insider now owns 85,622 shares in the company, valued at $5,196,399.18. The trade was a 17.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Sean Maduck also recently made the following trade(s):

• On Thursday, January 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00.

Corcept Therapeutics Trading Down 5.2 %

Corcept Therapeutics stock traded down $3.08 during mid-day trading on Tuesday, hitting $55.99. 1,889,312 shares of the company’s stock were exchanged, compared to its average volume of 1,005,169. The firm has a market capitalization of $5.91 billion, a P/E ratio of 44.44 and a beta of 0.58. Corcept Therapeutics Incorporated has a fifty-two week low of $20.84 and a fifty-two week high of $75.00. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $60.12 and its 200-day simple moving average is $51.82.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Analyst Ratings Changes

CORT has been the topic of several recent research reports. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. StockNews.com lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Piper Sandler raised their price target on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $115.00 price target on shares of Corcept Therapeutics in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.75.

Institutional Trading of Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CORT. Norges Bank acquired a new stake in shares of Corcept Therapeutics in the 4th quarter valued at about $42,055,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Corcept Therapeutics by 40.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock valued at $56,637,000 after purchasing an additional 352,947 shares during the period. Braun Stacey Associates Inc. acquired a new stake in shares of Corcept Therapeutics in the 4th quarter valued at about $14,935,000. FMR LLC grew its holdings in shares of Corcept Therapeutics by 24.6% in the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock valued at $63,122,000 after acquiring an additional 269,074 shares in the last quarter. Finally, Synergy Asset Management LLC grew its holdings in shares of Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after acquiring an additional 262,503 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.